CRISPR Therapeutics 주식 (NASDAQ: CRSP)

에 대한 최신 뉴스 CRISPR Therapeutics (NASDAQ:CRSP) 주식

CRISPR Therapeutics

Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Cathie Wood Bets On Baidu As Chinese AI Buzz Intensifies, Ark Loads Up On $12.4 Million Worth Of Stock

Equities

News

Markets

Tech

ETFs

AMZN

ARKF

ARKK

ARKQ

ARKW

BEAM

COIN

CRSP

MELI

PATH

RBLX

RPTX

2025년 4월 4일 금요일에 캐시 우드가 이끄는 아크 인베스트는 코인베이스 글로벌(NASDAQ:COIN), 아마존닷컴(NASDAQ:AMZN), 크리스퍼 테라퓨틱스 AG(NGM:CRSP), 빔 테라퓨틱스(NASDAQ:BEAM), 유아이패스(NYSE:PATH), 로블록스(NYSE:RBLX), 메르카도리브레(NASDAQ:MELI), 그리고 리페어 테라퓨틱스(NASDAQ:RPTX)를 포함한 여러 저명한 기업에 대해 상당한 거래를 했다.

아크 인베스트, 아마존 주식이 20% 이상 하락한 가운데 매수: 유아이패스, 로블록스 매각

Ark Invest's Cathie Wood Says Belief In Bitcoin's $1.5 Million Price Target By 2030 Has Grown

$BTC

DKNG

화요일(11일) 캐시 우드의 아크 인베스트는 템퍼스AI(NASDAQ:TEM), 블록(NYSE:XYZ), 드래프트킹스(NASDAQ:DKNG)과 관련해 주목할

아크 인베스트: 템퍼스AI에 지속 투자, 기술주 급락 후 블록 매도 등

Uber Weride

Mid Cap

Movers

Trading Ideas

AXSM

MKGAF

MKKGY

NVDA

RXRX

SWTX

TEVA

VNET

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 위라이드(NASDAQ:WRD)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:NVDA)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.

위라이드, 크리스퍼 및 진DX 등 지난주 최대 상승한 10개의 중형주 (2월 10일-2월 14일)

CRISPR Therapeutics AG

Dave Ramsey is known for helping people dig their way out of debt, one snowball at a time. He's blunt, he's bold, and that's exactly what people tune in for.
So when someone wrote in to ask if his famous strategy could work on a national level — specifically, if it could tackle the <a href="https://www.benzinga.com/personal-finance/25/03/44484869/its-not-like-they-can-repo-kentucky-dave-ramsey-breaks-down-the-36-trillion-national-debt-in-simple-terms-after-caller-asks-why-pay-it">government's $36 trillion in debt</a> — he didn't shy away.
The question came during an <a href="https://youtu.be/fS7-l8TEx-Y?si=uJ-JE3zxylShAqAB">episode of "The Dave Ramsey Show</a>" posted last week, where Ramsey and his daughter, Rachel Cruze, read a letter from Steve in Indiana. He had a simple, loaded question: Would Ramsey's debt snowball plan help the country climb out of its massive financial hole?
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Just for good measure, Steve threw in, "I wish Trump had you on the DOGE team."
Ramsey laughed, saying he doesn't exactly blend in with the D.C. crowd. He explained that while he's friendly with a few state governors, he doesn't really "fit in" anywhere in Washington. That said, he still had plenty to say about what he'd do if he were running the show.
And yes, he actually does believe some of the same debt-free principles could apply to the federal government.
"The principle of being debt-free still stands," Ramsey said. "And the principle of living on less than you make still stands."
But it wasn't just <a href="https://www.benzinga.com/personal-finance/24/12/42746966/debt-and-broke-are-the-norm-says-dave-ramsey-explains-why-normal-isnt-working-for-most-americans-and-how-to-take-control-of-your-money">basic budgeting advice</a>. Ramsey dove into the economics behind what he sees as a better way to generate revenue.
"To a certain degree, as you lower taxes, the economy heats up," he said. "Because the people that are making money are putting money back into their businesses, and they make yet more money — and they pay yet more taxes, even though the rate is lower."
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
That, he said, leads to the ultimate twist.
"If you lower taxes, it heats up the economy and you end up collecting more revenue," Ramsey explained. "Oddly enough, <a href="https://www.benzinga.com/markets/25/03/44295365/trump-wants-no-tax-for-americans-making-less-than-150000-a-year-says-howard-lutnick-thats-what-im-working-for">lowering taxes does work</a>. It seems oxymoronic."
He pointed to the Clinton-era budget as a rare example of balance in Washington, noting that the tax code at the time still reflected policies from the Reagan administration. The connection? The Laffer Curve, which is the theory that lower taxes can actually increase government revenue. Ramsey said it's been misunderstood or dismissed by critics, but in his view, the data holds up.
Of course, more income is only half the fix. The other half, Ramsey said, is cutting spending — and cutting deep.
"You cut the snot out of the expenses," he said. "If you could ever get it right-side up, where there's more income than outgo… then could you start to pay off the debt? Absolutely you could."
See Also: <a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a>
Ramsey praised the Trump administration for taking a bold stance on federal spending, saying it's the first time in his life he's seen a president willing to slash the budget <a href="https://www.benzinga.com/personal-finance/25/04/44726176/dave-ramsey-reveals-one-trait-among-successful-financial-transformations-few-people-have-the-courage-to-seek-out-change">without worrying about political fallout</a>. He compared it to personal finance — when people finally get serious about change, they stop caring about what others think. "You don't care what your broke brother-in-law thinks about your car," he said.&nbsp;
When it comes to managing debt, Ramsey's got the track record and the advice. Whether it scales to $36 trillion? That's above his pay grade.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
</ul>

Personal Finance

Dave Ramsey Was Asked How He'd Handle The Nation's $36 Trillion Debt: 'Oddly Enough, Lowering Taxes Does Work — It Seems Oxymoronic'

Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) has outperformed the market over the past 5 years by 61.0% on an annualized basis producing an average annual return of 75.0%. Currently, Antero Resources has a market capitalization of $10.68 billion. 
Buying $100 In AR: If an investor had bought $100 of AR stock 5 years ago, it would be worth $2,005.85 today based on a price of $34.31 for AR at the time of writing.
<h3>Antero Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744843510_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Antero Resources 5 Years Ago Would Be Worth Today

Gold has long been a cornerstone of personal finance strategies, prized for its role as a hedge against inflation and economic uncertainty. Investors have two primary avenues to gain exposure to gold: purchasing physical gold or investing in gold exchange-traded funds. 
Each approach offers unique advantages and drawbacks, making the right choice dependent on financial goals, risk tolerance and <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44836846/wall-streets-mood-turns-bleak-as-global-recession-fears-mount-fund-managers-slash-us-exposure">investment horizon.</a>
Physical Gold: Physical gold refers to tangible assets, such as gold bars, coins and jewelry. An investment in physical gold is appealing to some investors as it is independent of banks or financial institutions with no digital records or intermediaries involved. Gold's intrinsic value and historical role as a store of wealth also make it appealing for generational wealth transfer.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44841158/hongkong-post-stops-us-package-service-china-e-commerce-stocks-drop">Hongkong Post Stops US Package Service, China E-Commerce Stocks Drop&nbsp;</a>
"Amidst the recent stock market turbulence, we're seeing renewed interest in tangible, physical assets that exist outside traditional financial structures," Tim Schmidt, the founder of Gold IRA Custodians,<a href="https://www.cnbc.com/2025/04/11/is-this-a-good-time-to-buy-gold-experts-weigh-in.html"> told </a>CNBC.&nbsp;
However, the costs of secure storage and insurance can be high and the market for physical gold can be relatively illiquid with transactions sometimes incurring delays before a buyer or seller can be found. Also, physical gold does not generate interest or dividends so returns can only be realized when the gold is sold.&nbsp;
Gold ETFs: Investing in a gold-focused <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44836076/gold-fund-inflows-smash-record-with-80-billion-in-2025-these-etfs-are-riding-the-3300-surge">exchange-traded fund </a>can provide investors with exposure to gold's price movements without the need to own or store the metal directly.&nbsp;
"For most [investors], I would say a gold bullion-backed ETF makes the most sense," Sameer Samana, head of global equities and real assets at the Wells Fargo Investment Institute, told CNBC.
Both the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) and iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>), are backed by physical gold bullion held in secure vaults, and each share represents a specific amount of gold. 
Investors can also find exposure to gold through the VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>), tracking the performance of the NYSE Arca Gold Miners Index, and the VanEck Junior Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDXJ#NYSE">GDXJ</a>) which focuses on smaller, early-stage gold miners, offering higher growth potential but increased volatility. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/04/44817229/chinese-tiktok-influencers-expose-cheap-nike-lululemon-suppliers-to-bypass-trump-tariffs">Chinese TikTok Influencers &#8216;Expose&#8217; Cheap Nike, Lululemon Suppliers To Bypass Trump Tariffs&nbsp;</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

Commodities

Market Vectors ETF Trust Market Vectors Gold Miners

GDXJ

Gold Hits New Record Highs As Safe-Haven Demand Climbs: 2 Ways To Invest

Webull Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) shares closed Wednesday down more than 11% following a social media post suggesting that lawmakers are pushing for an investigation and <a href="https://www.benzinga.com/25/04/44837898/chinese-stocks-slide-as-trump-tariffs-surge-to-245-sparking-fears-of-price-hikes-and-delistings">potential delisting</a>.
What To Know: Fox Business senior correspondent Charles Gasparino said in an <a href="https://x.com/CGasparino/status/1912592400624611493">X post</a> Wednesday afternoon that lawmakers are ramping up pressure on the U.S. Securities and Exchange Commission to &#8220;investigate and possibly delist&#8221; Chinese discount brokerage firm Webull.
"Webull's deep ties to China have potentially severe national security implications and must be investigated by the SEC,&#8221; Sen.&nbsp;Tommy Tuberville&nbsp;(R-Ala.) reportedly said, according to Gasparino&#8217;s social media post.
The post indicates lawmakers are &#8220;aggressively&#8221; calling on the SEC to investigate the company.
Webull was founded in 2016 by former&nbsp;Alibaba&nbsp;and Xiaomi manager Wang Anquan, according to <a href="https://www.cnbc.com/2025/04/14/webull-stock-soars-in-second-trading-day-after-completing-spac-merger.html">CNBC</a>. Anquan reportedly remains the company's global CEO.
Webull went public via a special purpose acquisition company (SPAC) merger with SK Growth Opportunities on Monday. The stock surged out of the gates and has been extremely volatile since.
The company announced the closing of its business combination with SK Growth Opportunities on Wednesday. Webull also rang the opening bell at the Nasdaq.
&#8220;This next step in our company&#8217;s journey will position us to serve the growing number of experienced, digitally savvy retail investors who demand a more sophisticated retail trading partner that can grow with and serve them over decades,&#8221; said Anthony Denier, group president and U.S. CEO of Webull.
&#8220;Webull&#8217;s advanced trading and investment offerings make us the partner of choice for the next generation of retail investors looking to capitalize on the dynamic world of trading and investment.&#8221;
The news comes as trade tensions continue to rise between the U.S. and China. Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-04-15/chinese-stocks-trading-in-the-us-face-an-old-foe-delisting?embedded-checkout=true">reported</a> this week that Secretary of the Treasury Scott Bessent said all options are &#8220;on the table&#8221; when asked about potential delistings of Chinese stocks amid trade negotiations.
Chinese broker Futu Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) fell nearly 4% on Wednesday and was continuing to move lower in after-hours trading at last check. Other U.S.-listed Chinese stocks have been trending lower in recent sessions as the U.S.-China trade war continues to <a href="https://www.benzinga.com/markets/25/04/44831287/trump-administration-imposes-up-to-245-tariff-on-chinese-imports-amid-intensifying-trade-battle">escalate</a>. The IShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) closed Wednesday down 2.29% at $32.42, and the KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>) closed down more than 3% at $30.17.
Webull shares were bouncing back in after-hours trading at the time of writing, up 5.96% at $38.38, according to <a href="http://benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44846329/nvidias-china-sales-face-setback-as-h20-chip-restrictions-catch-key-buyers-off-guard-reuters">Nvidia&#8217;s China Sales Face Setback As H20 Chip Restrictions Catch Key Buyers Off Guard</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/tadaimages">Tada Images</a>/Shutterstock.

Government

Global

After-Hours Center

BULL

FUTU

KWEB

What's Going On With Webull Stock?

<a href="https://www.benzinga.com/news/25/03/44238467/warren-buffett-shares-biggest-investing-mistakes-433m-deal-that-cost-berkshire-billions-and-trillion-dollar-tech-stocks-he-missed">Warren Buffett</a> just leapfrogged Bill Gates to become the world&#8217;s sixth-richest person — and he did it the old-fashioned way: patience, discipline, and a mountain of cash. The 94-year-old investing legend has added a jaw-dropping $23 billion to his Fortune this year alone, boosting his net worth to $165 billion, according to the <a href="https://www.bloomberg.com/billionaires/profiles/warren-e-buffett/?utm_source=chatgpt.com">Bloomberg Billionaires Index</a>.
<h2 class="wp-block-heading">Investors Are Clinging to Buffett Like a Lifeboat</h2>
At a time when markets are swinging wildly and Big Tech is taking some heat, investors are turning to Buffett and Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>, BRK.B)) like he&#8217;s a financial North Star. Lountzis Asset Management President Paul Lountzis told <a href="https://www.businessinsider.com/warren-buffett-berkshire-hathaway-stock-market-cash-geico-abel-2025-3">Business Insider</a>, &#8220;Berkshire is a stable, solid ship in a sea of uncertainty right now."
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
That stability isn&#8217;t just hype. At the end of 2024, <a href="https://www.berkshirehathaway.com/2024ar/2024ar.pdf">Berkshire had $334.2 billion in cash</a>. The company also holds more than $272 billion in equities — including giants like Apple, Coca-Cola, and American Express.
Buffett has been running the show for 60 years. What started as a failing textile company is now <a href="https://companiesmarketcap.com/berkshire-hathaway/marketcap">a $1 trillion empire</a>. The company now has holdings that span everything from See&#8217;s Candies to BNSF Railway to Precision Castparts.&nbsp;
Berkshire&#8217;s stock has climbed over 5.5 million percent under his leadership — compared to the S&amp;P 500&#8217;s modest 39,000% in the same timeframe, reported by<a href="https://www.businessinsider.com/warren-buffett-berkshire-hathaway-stock-market-cash-geico-abel-2025-3"> Business Insider</a>. That&#8217;s a 20% annualized return for six decades.
One of the recent engines of growth is none other than geico, Berkshire&#8217;s auto insurance arm. After years of lackluster performance, geico roared back in 2024 with a pre-tax underwriting profit of $7.81 billion according to <a href="https://coverager.com/geico-ends-2024-with-7-8-billion-profit/">Coverager</a> — a 114.9% spike.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Geico CEO Todd Combs, who helps manage Berkshire&#8217;s investments, has been tightening operations and updating its underwriting processes. In his<a href="https://www.berkshirehathaway.com/letters/2024ltr.pdf"> annual shareholder letter</a> to Berkshire investors, Buffett called geico &#8220;a long-held gem that needed major repolishing&#8221; and praised its turnaround as &#8220;spectacular.&#8221;
That boost helped Berkshire&#8217;s operating earnings soar 71% year-over-year to a record $14.53 billion in the <a href="https://www.berkshirehathaway.com/news/feb2225.pdf">latest quarter</a>, outpacing even the so-called Magnificent 7 tech giants. ​As of the end of 2024, Geico's workforce had been trimmed to 28,247 employees, marking a decrease of more than 10,000 people since 2021.
Buffett&#8217;s strategy has always shone brightest during downturns. Back in 2008, while most investors were panicking, he was striking deals with <a href="https://www.benzinga.com/personal-finance/25/03/44552280/banks-will-never-go-out-of-business-jim-cramer-says-jpmorgan-is-too-cheap-to-ignore-as-it-hits-r">Goldman Sachs</a>, General Electric, Mars, Dow, and Swiss Re. Today, Berkshire&#8217;s $334 billion cash cushion gives Buffett — or, more accurately, his successor — room to repeat that playbook.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
</ul>

Warren Buffett Surpasses Bill Gates With $165 Billion Fortune – 'Berkshire Is A Stable Ship In A Sea Of Uncertainty'

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) has outperformed the market over the past 5 years by 14.47% on an annualized basis producing an average annual return of 28.47%. Currently, Eaton Corp has a market capitalization of $104.25 billion. 
Buying $100 In ETN: If an investor had bought $100 of ETN stock 5 years ago, it would be worth $345.56 today based on a price of $263.79 for ETN at the time of writing.
<h3>Eaton Corp's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744842612_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Eaton Corp 5 Years Ago Would Be Worth Today

A fresh round of U.S. export restrictions on China&#8217;s AI capabilities has caught NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) off guard, with <a href="https://www.benzinga.com/etfs">ETFs with high exposure to the chip giant</a> are feeling the pain (or gain, in some cases). While Nvidia plummeted 6.87% by market close Wednesday, some semiconductor-themed ETFs moved sharply.
The unexpected regulatory shock, <a href="https://www.benzinga.com/government/regulations/25/04/44845141/nvidia-drags-wall-street-down-gold-defies-gravity-ahead-of-powell-remarks-whats-driving-ma">preventing Nvidia from sending its high-margin H20 AI chips to China</a>, has triggered a broader selloff in the tech-heavy sector, rekindling arguments on geopolitical risk, earnings visibility, and the role of ETFs in escalating such shocks.
Advanced Micro Devices Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) MI308 chips also come under the new licensing regime and fell 6%, adding to the broader pressure across chipmakers.
<h1 class="wp-block-heading">ETF Reaction: Bloodbath For Some, Jackpot For Others</h1>
The ripple effects were most apparent in semiconductor and Nvidia-focused ETFs, many of which took deep intraday losses — while inverse products registered explosive gains.
GraniteShares 2x Short NVDA Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVD#NASDAQ">NVD</a>) skyrocketed more than 13% on Wednesday, with short selling in Nvidia paying off during the rout. The fund, providing 2x inverse daily leverage on Nvidia&#8217;s stock, has been a most significant volatility trade during earnings and regulatory events.
Strive U.S. Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOC#NYSE">SHOC</a>) fell over 4%. SHOC, with its heavy weighting in <a href="https://www.benzinga.com/topic/semiconductors">fabless semiconductor companies</a> such as Nvidia (23% <a href="https://www.strivefunds.com/shoc">weightage</a>) and AMD (4.74% weightage), is especially susceptible to revenue shock from export policy shifts.
VanEck Fabless Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMHX#NASDAQ">SMHX</a>) fell more than 3%, following the general market jitters. Nvidia is one of the key holdings in SMHX, with the biggest weightage of <a href="https://www.vaneck.com/us/en/investments/fabless-semiconductor-etf-smhx/holdings/">21.4%</a>, making it extremely sensitive to any slowdown in AI chip sales.
These movements represent how closely ETFs have become tied to a few megacap tech narratives — rendering them both effective and vulnerable vehicles for sector bets.
<h1 class="wp-block-heading">What Happened?</h1>
Markets soured on Wednesday following the U.S. government&#8217;s decision to tighten <a href="https://www.benzinga.com/topic/tariffs">AI chip exports to China</a> and arms-embargoed countries. Nvidia, whose H20 chips were specifically designed to meet prior export controls, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001045810/000104581025000082/nvda-20250409.htm">announced </a>that it will incur a $5.5 billion charge for excess inventory, purchase commitments, and reserves — essentially discounting the failure of its China-facing H20 strategy.
Crafted specifically to meet previous export regulations under the Biden administration, the H20 chip was made China-sale-specific and had enabled Nvidia to keep a firm grip on the market despite continued tensions. In 2024 alone, the chips were estimated to have brought in $12 billion to $15 billion in revenue.
The new measures now make the old playbook dated. AMD also conceded the blow in a Wednesday <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000002488/000000248825000039/amd-20250415.htm">report</a>, cautioning that restrictions on its MI308 chips could generate an $800 million revenue blow.
The new regulations — universally regarded as a crackdown on loopholes — will likely impact Nvidia&#8217;s fiscal 2026 revenue by 6%–10%, <a href="https://www.benzinga.com/25/04/44844084/nvidias-h20-chip-ban-could-lead-to-manageable-sales-drop-bank-of-america-says">Bank of America analyst Vivek Arya estimated</a>. While Arya labeled the risks &#8220;manageable&#8221; and reaffirmed a Buy rating with a $160 price target, the market reaction was swift and severe.
Also Read: <a href="https://www.benzinga.com/25/04/44799456/chip-shock-3-hot-semiconductor-etfs-to-watch-as-trumps-tariff-bomb-ticks">Chip Shock: 3 Hot Semiconductor ETFs To Watch As Trump&#8217;s Tariff Bomb Ticks</a>
<h1 class="wp-block-heading">What&#8217;s Next For Nvidia-Focused Funds?</h1>
In spite of the carnage on the day, some analysts are of the view that the sell-off can provide a tactical entry. Bank of America&#8217;s Arya noted Nvidia is currently trading at about 20 times estimated 2025 earnings — less than its historical valuation range of 23x–25x — and that its future GB300 Blackwell Ultra chips have the potential to re-spark the growth story by the second half of 2025.
Yet, near-term volatility is unlikely to fade, especially with geopolitics now a key driver of chipmaker valuations.
ETF investors, meanwhile, face a tough balancing act: whether to double down on U.S. AI chip dominance or hedge against further policy shocks that could derail near-term earnings.
One thing is clear — Nvidia's dominance may still be intact, but its ETF exposure just made a lot more complicated.
Read Next:<a href="https://www.benzinga.com/25/04/44848475/unlimited-unpacks-hedge-fund-alpha-with-launch-of-hfgm-etf"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/04/44848475/unlimited-unpacks-hedge-fund-alpha-with-launch-of-hfgm-etf">Unlimited Unpacks Hedge Fund Alpha With Launch Of ETF Without High Fees, Lock-Up Features</a></li>
</ul>
Photo: Shutterstock

EA Series Trust Strive U.S. Semiconductor ETF

SHOC

SMHX

Chipwrecked: Nvidia's Export Ban Triggers ETF Meltdown (And One Big Winner)

Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has outperformed the market over the past 20 years by 6.62% on an annualized basis producing an average annual return of 14.45%. Currently, Microsoft has a market capitalization of $2.77 trillion. 
Buying $100 In MSFT: If an investor had bought $100 of MSFT stock 20 years ago, it would be worth $1,487.63 today based on a price of $372.15 for MSFT at the time of writing.
<h3>Microsoft's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744841712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MSFT

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

<a href="https://www.bloomberg.com/news/articles/2025-04-16/alcoa-reports-20-million-tariff-hit-on-imports-from-canada">https://www.bloomberg.com/news/articles/2025-04-16/alcoa-reports-20-million-tariff-hit-on-imports-from-canada</a>

General

Alcoa Reports $20M Tariff Hit On Imports From Canada- Bloomberg

VTAK

Catheter Precision Negotiating Asset Purchase Agreement With Cardionomic

In the preceding three months, 7 analysts have released ratings for Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Glaukos, revealing an average target of $170.86, a high estimate of $200.00, and a low estimate of $140.00. This upward trend is apparent, with the current average reflecting a 4.27% increase from the previous average price target of $163.86.
<img src="https://www.benzinga.com/files/images/story/2025/1744840876_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Glaukos. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anthony Petrone &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $175.00&#x7C;$200.00 &#x7C; 
&#x7C;Matt O'Brien &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $165.00&#x7C;$180.00 &#x7C; 
&#x7C;Richard Newitter &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $140.00&#x7C;$185.00 &#x7C; 
&#x7C;Larry Biegelsen &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $160.00&#x7C;$153.00 &#x7C; 
&#x7C;David Saxon &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $176.00&#x7C;$149.00 &#x7C; 
&#x7C;Anthony Petrone &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $200.00&#x7C;$140.00 &#x7C; 
&#x7C;Matt O'Brien &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $180.00&#x7C;$140.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Glaukos. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Glaukos's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Glaukos analyst ratings.</a>
<h2>Discovering Glaukos: A Closer Look</h2>
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
<h3>Glaukos: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Glaukos showcased positive performance, achieving a revenue growth rate of 28.09% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Glaukos's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -31.83%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.68%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Glaukos's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.53%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.13, Glaukos adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

GKOS

Forecasting The Future: 7 Analyst Projections For Glaukos

9 analysts have shared their evaluations of MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $47.78, a high estimate of $60.00, and a low estimate of $36.00. Surpassing the previous average price target of $46.22, the current average has increased by 3.38%.
<img src="https://www.benzinga.com/files/images/story/2025/1744840865_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of MGM Resorts International by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Stephen Grambling &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $36.00&#x7C;$37.00 &#x7C; 
&#x7C;Stephen Grambling &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $41.00&#x7C;$39.00 &#x7C; 
&#x7C;Chad Beynon &#x7C;Macquarie &#x7C;Maintains &#x7C;Outperform &#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;George Choi &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $50.00&#x7C;$48.00 &#x7C; 
&#x7C;Daniel Politzer &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $46.00&#x7C;$44.00 &#x7C; 
&#x7C;Jordan Bender &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;Brandt Montour &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $47.00&#x7C;$45.00 &#x7C; 
&#x7C;Ben Chaiken &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $60.00&#x7C;$56.00 &#x7C; 
&#x7C;Steven Wieczynski &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $50.00&#x7C;$47.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to MGM Resorts International. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MGM Resorts International compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for MGM Resorts International's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of MGM Resorts International's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MGM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MGM Resorts International analyst ratings.</a>
<h2>Get to Know MGM Resorts International Better</h2>
MGM Resorts is the largest resort operator on the Las Vegas Strip with 37,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Park MGM, Luxor, New York-New York, and Bellagio. The Strip contributed approximately 59% of total EBITDAR in 2024. MGM also owns US regional assets, which represented a low 20s share of 2024 EBITDAR (MGM's Macao EBITDAR was 21% of the total in 2024). MGM's US sports and i-gaming operations are currently a high-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM China casinos with a new property that opened on the Cotai Strip in early 2018. We estimate MGM will open a resort in Japan in 2030.
<h3>Understanding the Numbers: MGM Resorts International's Finances</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: MGM Resorts International's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -0.66%. This indicates a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: MGM Resorts International's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.55%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): MGM Resorts International's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.94% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): MGM Resorts International's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.36%, the company may face hurdles in achieving optimal financial performance.
Debt Management: MGM Resorts International's debt-to-equity ratio is below the industry average. With a ratio of 10.45, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where MGM Resorts International Stands With Analysts

Across the recent three months, 6 analysts have shared their insights on Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Red Rock Resorts, presenting an average target of $53.67, a high estimate of $61.00, and a low estimate of $43.00. Experiencing a 1.21% decline, the current average is now lower than the previous average price target of $54.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1744840858_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Red Rock Resorts among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Stephanie Grambling &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $43.00&#x7C;$45.00 &#x7C; 
&#x7C;Joseph Stauff &#x7C;Susquehanna &#x7C;Lowers &#x7C;Positive &#x7C; $52.00&#x7C;$61.00 &#x7C; 
&#x7C;Steve Wieczynski &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $54.00&#x7C;$50.00 &#x7C; 
&#x7C;Joseph Stauff &#x7C;Susquehanna &#x7C;Raises &#x7C;Positive &#x7C; $61.00&#x7C;$60.00 &#x7C; 
&#x7C;Ben Chaiken &#x7C;Mizuho &#x7C;Raises &#x7C;Neutral &#x7C; $52.00&#x7C;$44.00 &#x7C; 
&#x7C;Joseph Stauff &#x7C;Susquehanna &#x7C;Lowers &#x7C;Positive &#x7C; $60.00&#x7C;$66.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Red Rock Resorts. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Red Rock Resorts compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Red Rock Resorts's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Red Rock Resorts's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RRR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Red Rock Resorts analyst ratings.</a>
<h2>Unveiling the Story Behind Red Rock Resorts</h2>
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
<h3>A Deep Dive into Red Rock Resorts's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Red Rock Resorts displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.13%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Red Rock Resorts's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.4%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Red Rock Resorts's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 23.85% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Red Rock Resorts's ROA stands out, surpassing industry averages. With an impressive ROA of 1.16%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 15.87, Red Rock Resorts faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Red Rock Resorts In The Eyes Of 6 Experts

Across the recent three months, 26 analysts have shared their insights on MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $292.0, a high estimate of $351.00, and a low estimate of $190.00. A 19.91% drop is evident in the current average compared to the previous average price target of $364.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1744840850_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of MongoDB's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Sanjit Singh &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $235.00&#x7C;$315.00 &#x7C; 
&#x7C;Matthew Broome &#x7C;Mizuho &#x7C;Lowers &#x7C;Neutral &#x7C; $190.00&#x7C;$250.00 &#x7C; 
&#x7C;Brad Reback &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $275.00&#x7C;$340.00 &#x7C; 
&#x7C;Tyler Radke &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $330.00&#x7C;$430.00 &#x7C; 
&#x7C;Miller Jump &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $275.00&#x7C;$300.00 &#x7C; 
&#x7C;Steve Koenig &#x7C;Macquarie &#x7C;Lowers &#x7C;Neutral &#x7C; $215.00&#x7C;$300.00 &#x7C; 
&#x7C;Patrick Colville &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Perform &#x7C; $240.00&#x7C;$275.00 &#x7C; 
&#x7C;Sanjit Singh &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $315.00&#x7C;$350.00 &#x7C; 
&#x7C;Kash Rangan &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $335.00&#x7C;$390.00 &#x7C; 
&#x7C;Brad Reback &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $340.00&#x7C;$425.00 &#x7C; 
&#x7C;Miller Jump &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $300.00&#x7C;$400.00 &#x7C; 
&#x7C;Ittai Kidron &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $330.00&#x7C;$400.00 &#x7C; 
&#x7C;Rishi Jaluria &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $320.00&#x7C;$400.00 &#x7C; 
&#x7C;Brent Bracelin &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $280.00&#x7C;$425.00 &#x7C; 
&#x7C;Raimo Lenschow &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $280.00&#x7C;$330.00 &#x7C; 
&#x7C;Daniel Ives &#x7C;Wedbush &#x7C;Lowers &#x7C;Outperform &#x7C; $300.00&#x7C;$360.00 &#x7C; 
&#x7C;Bradley Sills &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $286.00&#x7C;$420.00 &#x7C; 
&#x7C;William Power &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $300.00&#x7C;$390.00 &#x7C; 
&#x7C;Mike Cikos &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $270.00&#x7C;$415.00 &#x7C; 
&#x7C;David Hynes &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $320.00&#x7C;$385.00 &#x7C; 
&#x7C;Blair Abernethy &#x7C;Rosenblatt &#x7C;Lowers &#x7C;Buy &#x7C; $305.00&#x7C;$350.00 &#x7C; 
&#x7C;Andrew Nowinski &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $225.00&#x7C;$365.00 &#x7C; 
&#x7C;Blair Abernethy &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $350.00&#x7C;$350.00 &#x7C; 
&#x7C;Yun Kim &#x7C;Loop Capital &#x7C;Lowers &#x7C;Buy &#x7C; $350.00&#x7C;$400.00 &#x7C; 
&#x7C;Patrick Colville &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Perform &#x7C; $275.00&#x7C;$350.00 &#x7C; 
&#x7C;Colin Liu &#x7C;China Renaissance &#x7C;Announces &#x7C;Buy &#x7C; $351.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MongoDB. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MongoDB compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for MongoDB's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of MongoDB's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MDB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MongoDB analyst ratings.</a>
<h2>Unveiling the Story Behind MongoDB</h2>
Founded in 2007, MongoDB is a document-oriented database. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
<h3>MongoDB: Financial Performance Dissected</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3M period, MongoDB showcased positive performance, achieving a revenue growth rate of 19.74% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: MongoDB's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): MongoDB's ROE stands out, surpassing industry averages. With an impressive ROE of 0.74%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): MongoDB's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.48% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where MongoDB Stands With Analysts

Ratings for PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $20.67, a high estimate of $26.00, and a low estimate of $17.00. Observing a downward trend, the current average is 12.67% lower than the prior average price target of $23.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1744840830_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive PagerDuty is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Sanjit Singh &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $17.00&#x7C;$20.00 &#x7C; 
&#x7C;Kash Rangan &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $18.00&#x7C;$21.00 &#x7C; 
&#x7C;Kingsley Crane &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $23.00&#x7C;$24.00 &#x7C; 
&#x7C;Matthew Hedberg &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $22.00&#x7C;$24.00 &#x7C; 
&#x7C;Joel Fishbein &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $26.00&#x7C;$30.00 &#x7C; 
&#x7C;Koji Ikeda &#x7C;B of A Securities &#x7C;Lowers &#x7C;Underperform &#x7C; $18.00&#x7C;$23.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to PagerDuty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PagerDuty compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for PagerDuty's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of PagerDuty's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on PagerDuty analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering PagerDuty: A Closer Look</h2>
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
<h3>Unraveling the Financial Story of PagerDuty</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, PagerDuty showcased positive performance, achieving a revenue growth rate of 9.3% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: PagerDuty's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -8.73%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -8.78%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): PagerDuty's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -1.18%, the company showcases efficient use of assets and strong financial health.
Debt Management: PagerDuty's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.57, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PagerDuty Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

In the current market session, CACI International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) stock price is at $414.93, after a 0.55% drop. However, over the past month, the company's stock increased by 7.25%, and in the past year, by 13.97%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744840820_0.png" alt="Past Year Chart" />

<h3>Evaluating CACI International P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 34.4 in the Professional Services industry, CACI International Inc. has a lower P/E ratio of 19.58. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744840820_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

CACI

A Look Into CACI International Inc's Price Over Earnings

Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) has outperformed the market over the past 5 years by 8.63% on an annualized basis producing an average annual return of 22.63%. Currently, Primerica has a market capitalization of $8.44 billion. 
Buying $100 In PRI: If an investor had bought $100 of PRI stock 5 years ago, it would be worth $264.88 today based on a price of $255.11 for PRI at the time of writing.
<h3>Primerica's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744840815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

In the latest quarter, 5 analysts provided ratings for LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated LiveRamp Holdings and provided 12-month price targets. The average target is $39.6, accompanied by a high estimate of $45.00 and a low estimate of $28.00. This current average represents a 1.0% decrease from the previous average price target of $40.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744840815_0_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of LiveRamp Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Stan Zlotsky &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $28.00&#x7C;$38.00 &#x7C; 
&#x7C;Mark Zgutowicz &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $45.00&#x7C;$45.00 &#x7C; 
&#x7C;Kirk Materne &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;Outperform &#x7C; $45.00&#x7C;$40.00 &#x7C; 
&#x7C;Stan Zlotsky &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $38.00&#x7C;$35.00 &#x7C; 
&#x7C;Mark Zgutowicz &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $42.00&#x7C;$42.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to LiveRamp Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of LiveRamp Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of LiveRamp Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of LiveRamp Holdings's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RAMP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on LiveRamp Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into LiveRamp Holdings's Background</h2>
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
<h3>LiveRamp Holdings: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: LiveRamp Holdings's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 12.39%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.74%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): LiveRamp Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of 0.92%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.04.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RAMP

What 5 Analyst Ratings Have To Say About LiveRamp Holdings

Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) has outperformed the market over the past 5 years by 5.53% on an annualized basis producing an average annual return of 19.52%. Currently, Corteva has a market capitalization of $40.43 billion. 
Buying $1000 In CTVA: If an investor had bought $1000 of CTVA stock 5 years ago, it would be worth $2,403.57 today based on a price of $59.20 for CTVA at the time of writing.
<h3>Corteva's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744839914_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTVA

$1000 Invested In Corteva 5 Years Ago Would Be Worth This Much Today

SKK Holdings Limited Receives Nasdaq Notification Letter Regarding Minimum Price Deficiency

Health Care

Management

Press Releases

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Earnings

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

The Future of Stem Cell Investing: Spotlight on Smaller Innovators

CRISPR Therapeutics Announces Transition of Chief Operating Officer

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

ADIA

BLUE

FATE

MESO

Needham

Citigroup

Morgan Stanley

Evercore ISI Group

Goldman Sachs

2025년 4월 4일 금요일에 캐시 우드가 이끄는 아크 인베스트는 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), 크리스퍼 테라퓨틱스 AG(NGM:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/crsp" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CRSP">CRSP</a>), 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), 유아이패스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), 로블록스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>), 메르카도리브레(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), 그리고 리페어 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>)를 포함한 여러 저명한 기업에 대해 상당한 거래를 했다.
COIN 거래
아크 인베스트는 여러 ETF를 통해 코인베이스 글로벌의 주식을 구매했다. 아크 인베스트의 ARK 핀테크 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 12,187주를 구매했으며, ARK 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 각각 54,988주와 15,982주를 추가했다.
구매된 COIN 주식의 총 가치는 마지막 종가 160.55달러를 기준으로 약 1350만 달러에 해당한다.
AMZN 거래
아마존닷컴도 아크 인베스트로부터 상당한 매수세를 보았다. ARKF, ARKK, 그리고 ARK 자율 기술 및 로보틱스 ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>)는 각각 9,018주, 25,528주 및 8,408주를 구매했다.
아마존의 마지막 종가가 171.0달러인 점을 고려할 때, 구매된 주식의 총 가치는 약 740만 달러이다.
CRSP 및 BEAM 거래
ARKK 기금은 크리스퍼 테라퓨틱스 AG의 69,011주와 빔 테라퓨틱스의 142,713주를 구매했다. 각각의 마지막 종가가 32.65달러와 15.27달러인 점을 바탕으로, 구매된 CRSP 및 BEAM 주식의 총 가치는 약 350만 달러이다.
PATH 거래
아크 인베스트의 ARKK는 유아이패스 주식회사의 448,505주를 매도했으며, ARKQ는 147,575주를 매도했다. ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 323,575주를 매도했으며, ARKF 기금은 434,637주를 매도했다.
RBLX, MELI, 및 RPTX 거래
아크 인베스트는 로블록스와 메르카도리브레의 주식을 여러 ETF를 통해 매도했다. 또한, ARKG 기금은 리페어 테라퓨틱스의 32,613주를 매도했으며, 이는 마지막 종가 1.0달러를 기준으로 약 32,613달러에 해당한다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/25/04/44652222/trumps-tariffs-may-shift-us-spending-from-goods-to-services-creating-uncertainty-for-ecommerce-and-advertising-industries-analyst-warns">관세가 최종 수요에 영향을 미칠 것: 골드만삭스 분석가가 기업 지출 및 고용에 대한 저항을 예상한다</a> </li>
</ul>
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 작성되었으며, Benzinga 편집자에 의해 검토 및 게시되었다.
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화요일(11일) 캐시 우드의 아크 인베스트는 템퍼스AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 블록(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>), 드래프트킹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)과 관련해 주목할 만한 거래를 시행했다. 이는 시장 변동성과 아크 인베스트의 전략적 포지셔닝 속에서 나타났다.
<h3>템퍼스AI 거래</h3>
아크 인베스트의 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)가 종가 45.58달러를 기준으로 약 429만 달러에 달하는 템퍼스AI 주식 94,251주를 대량으로 매입했다. 템퍼스AI는 최근 4분기 실적을 발표하면서 매출은 감소했지만 주당순이익은 증가했다고 밝혔다. 매출 부진에도 불구하고 회사는 강력한 가이던스를 제시했으며, 이는 아크 인베스트의 지분 확대 결정에 영향을 미쳤을 수 있다.
최근 기술 업종 침체로 특징지어지는 시장 환경에서 아크 인베스트는 템퍼스AI와 같은 기업의 주식을 적극적으로 인수하고 있다. 월요일(10일) 기술주 폭락 속에서 우드는 1,323만 달러 상당의 <a href="https://www.benzinga.com/25/03/44239652/cathie-wood-goes-on-shopping-spree-amid-tech-bloodbath-monday-loads-up-on-tesla-palantir-coinbase-and-these-stock" target="_blank" rel="noopener">템퍼스AI 주식을 매입했다.</a>
<h3>블록 거래</h3>
같은 날, 아크 인베스트의 ARKK ETF는 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 중심 기업 블록의 주식 203,659주를 종가 55.29달러에 약 1,126만 달러에 매각했다. 블록의 최근 실적 보고서에 따르면 매출이 <a href="https://in.benzinga.com/news/earnings/25/02/43867724/block-shares-sink-after-q4-revenue-miss-ceo-jack-dorsey-expects-to-end-year-at-rule-of-40-run-rate" target="_blank" rel="noopener">예상치에 미치지 못했다.</a>
매출 부진에도 불구하고 블록의 CEO인 잭 도시(Jack Dorsey)는 연말까지 "Rule of 40"을 달성할 수 있을 것으로 낙관하고 있다.
<h3>드래프트킹스 거래</h3>
아크 인베스트는 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 드래프트킹스 보유 지분을 줄였다. 이는 종가 38.66달러를 기준으로 약 896,718달러에 해당한다. 드래프트킹스는 최근 스포츠 베팅 업계가 어려운 시기에 <a href="https://www.benzinga.com/general/sports-betting/25/02/43748897/draftkings-lost-some-games-but-won-the-quarter-analyst" target="_blank" rel="noopener">예상치를 하회한 매출</a>을 포함한 4분기 실적을 발표했다.
매출 부진에도 불구하고 애널리스트들은 드래프트킹스의 회복력과 미래 성장 잠재력을 강조했다.
<h3>기타 주요 거래</h3>
<ul>
<li>ARKF, ARKQ, ARKK 통해 로쿠(ROKU) 주식 매도</li>
<li>ARKF와 ARKW 통해 이보타(IBTA) 주식 매수</li>
<li>ARKF, ARKK, ARKW 통해 로블록스(RBLX) 주식 매도</li>
<li>ARKG 통해 케어Dx(CDNA) 주식 매도</li>
<li>ARKK, ARKG 통해 크리스퍼 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) 주식 6,495주 매수</li>
</ul>
이미지: Shutterstock 
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 위라이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.
2. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)의 주식이 43.45% 상승했다. 이는 트럼프 대통령이 중국에서 오는 $800 이하의 소포에 대한 관세를 연기했다고 보도된 후 발생한 일이다. 또한, 중국의 딥시크(DeepSeek) AI 모델에 대한 낙관론도 최근 주가를 끌어올렸다.
3. 스프링웍스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>)의 주식이 42.58% 상승했다. 이는 머크 그룹(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKGAF#OTC">MKGAF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKKGY#OTC">MKKGY</a>)가 회사를 인수하기 위한 고급 논의를 진행 중이라고 발표한 후 발생한 일이다.
4. 리커젼 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>)의 주식이 40.59% 증가했다.
5. 세이블 오프쇼어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>)의 주식이 39.09% 상승했다.
6. 진DX 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)의 주식이 28.23% 상승했다. 이는 회사가 울트라래피드 전장유전체 시퀀싱(UltraRapid Whole Genome Sequencing)을 발표하여 48시간 내에 실행 가능한 결과를 제공한다고 발표한 후 발생한 일이다.
7. 브이넷 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>)의 주식이 28.22% 상승했다. 이는 지난 주 중국의 딥시크 AI 모델과 관련된 AI 경쟁 우려로 하락한 후 반등 가능성이 제기된 것으로 보인다.
8. 인스페리티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>)의 주식이 25.99% 증가했다. 이는 회사가 예상보다 좋은 4분기 결과를 발표한 후 발생한 일이다.
9. 크리스퍼 테라퓨틱스 AG(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>)의 주식이 25.21% 상승했다. 이는 회사가 예상보다 좋은 4분기 재무 결과를 발표한 후 여러 애널리스트들이 주가 전망을 상향 조정한 후 발생한 일이다.
10. 액섬 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>)의 주식이 24.01% 상승했다. 이는 회사가 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)과의 모든 특허 소송을 해결하기 위한 합의에 도달한 후 발생한 일이다. 여러 애널리스트들이 주가 전망을 상향 조정했다.
다음 읽기:
<a href="https://kr.benzinga.com/news/usa/stocks/%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%9D%B8%ED%85%94-%EC%95%8C%EB%A6%AC%EB%B0%94%EB%B0%94-%EB%B0%8F-cvs-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%83%81%EC%8A%B9%ED%95%9C-12/" target="_blank" rel="noopener">슈퍼 마이크로, 인텔, 알리바바 및 CVS 등 지난주 상승한 12개 대형주 (2월 10일-2월 14일)</a>
<a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7-%EA%B3%A0%EB%8C%80%EB%94%94-%EB%B0%8F-%ED%8A%B8%EB%A0%88%EC%9D%B4%EB%93%9C-%EB%8D%B0%EC%8A%A4%ED%81%AC%EB%8A%94-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%ED%95%98%EB%9D%BD%ED%95%9C-11/" target="_blank" rel="noopener">레딧, 고대디 및 트레이드 데스크는 등 지난주 하락한 11개의 대형주 (2월 10일~2월 14일)</a>
사진 출처: WeRide
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

금요일에 캐시 우드가 이끄는 아크 인베스트가 크리스퍼 테라퓨틱스 AG(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), 10X 지노믹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>), 로블록스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>), 아처 에비에이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), 누 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>), 아디옌 NV(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADYEY#OTC">ADYEY</a>), 애콜레이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) 그리고 에어로바이런먼트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>)와 관련된 주요 거래를 했다.
CRSP 거래
아크 인베스트는 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)와 Ark Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 크리스퍼 테라퓨틱스의 주식을 매수했다. ARKG ETF는 43,467 주를, ARKK ETF는 248,748 주를 매입했다.
같은 날의 종가인 41.59달러를 기준으로, 구매한 주식의 총 가치는 약 12.14 백만 달러에 해당한다.
TXG 거래
또 다른 중요한 매수는 10X 지노믹스였다. 아크 인베스트는 ARKG ETF에 11,137 주를 추가하고 ARKK ETF에 63,395 주를 추가했다. 종가가 15.00달러인 경우, 구매한 주식의 총 가치는 약 1.12 백만 달러이다.
RBLX 및 ACHR 거래
매도 측면에서는 아크 인베스트가 로블록스와 아처 에비에이션의 보유 주식을 줄였다. 이 회사는 ARKK ETF에서 RBLX 주식 46,459 주와 ACHR 주식 374,904 주를 매도했다. 각각의 종가가 71.07달러와 9.45달러인 경우, 매도된 주식의 총 가치는 약 4.12 백만 달러이다.
기타 주요 거래:
아크 인베스트는 ARKG ETF에서 애콜레이드 주식 307,632 주를 매도했다.
또한, ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)에서 누 홀딩스와 아디옌 NV의 보유 주식을 각각 300 주와 5,600 주로 줄였다.
아크 인베스트는 ARK Space Exploration &amp; Innovation ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>)에서 에어로바이런먼트 주식 2,671 주를 매도했다.
이 거래들은 아크 인베스트의 전략과 현재 집중하고 있는 섹터를 엿볼 수 있게 한다. 이 회사의 움직임은 역사적으로 강력한 성과로 인해 투자자들에 의해 주의 깊게 관찰되고 있다.
다음 읽기:
<a href="https://kr.benzinga.com/news/usa/stocks/%EC%95%84%ED%81%AC-%EC%9D%B8%EB%B2%A0%EC%8A%A4%ED%8A%B8-ai-%EA%B2%BD%EC%9F%81-%EA%B0%80%EC%97%B4-%EC%86%8D-%ED%8C%94%EB%9E%80%ED%8B%B0%EC%96%B4-%EC%A3%BC%EC%8B%9D-1%EC%B2%9C%EB%A7%8C-%EB%8B%AC/" target="_blank" rel="noopener">캐시 우드의 아크 인베스트가 AI 경쟁이 치열해짐에 따라 팔란티어 주식 1천만 달러 어치를 매각</a>
면책 조항: 이 콘텐츠는 AI 도구의 도움으로 부분적으로 제작되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.
사진 제공: Ark Invest
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Biotech

ACCD

ACHR

ADYEY

ARKG

ARKX

AVAV

아크 인베스트 크리스퍼 테라퓨틱스 투자로 생명공학에 베팅, 로블록스에서 매도

구글 모기업 알파벳의 자회사인 스타트업 아이소모픽 랩스(Isomorphic Labs)는 올해 연말까지 최초의 인공지능(AI) 설계 의약품의 임상시험을 시작할 예정이다. 주요 기술 기업들이 AI 기반 의료 솔루션에 대한 투자를 늘리면서 제약 개발의 중요한 이정표가 될 것으로 보인다.
무슨 일 있었나: 다보스에서 열린 세계경제포럼에서 아이소모픽 랩스 설립자인 데미스 하사비스(Demis Hassabis)는 회사가 종양, 심혈관 질환, 신경 퇴화 등 주요 질병 분야를 목표로 하고 있다고 파이낸셜타임스와의 <a href="//www.ft.com/content/41b51d07-0754-4ffd-a8f9-737e1b1f0c2e"" target="_blank" rel="noopener">인터뷰에서 말했다.</a>
아이소모픽 랩스는 이미 6개의 신약 개발 프로그램을 위해 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) 및 노바티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)와 파트너십을 체결했다.
최근 노벨 화학상을 수상한 하사비스는 "보통 하나의 약을 발견하는 데 평균 5년에서 10년이 걸린다&#8221;며 &#8220;이를 10배로 단축할 수 있다면 인류 건강에 놀라운 혁명이 될 것&#8221;이라고 말했다.
왜 중요한가: 이번 아이소모픽 랩스의 발표는 오라클(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>)이 48시간 이내에 개인 맞춤형 치료를 제공할 수 있는 AI 기반 암 백신 시스템에 대한 계획을 발표한 이후 나온 것이다. 오라클의 이니셔티브는 <a href="https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment" target="_blank" rel="noopener">5,000억 달러 규모의 AI 인프라 프로젝트</a> &#8216;스타게이트&#8217;의 일환으로 오픈AI 및 소프트뱅크 그룹과 협력한다.
최근 AI 기반 신약 개발에 대한 투자가 탄력을 받고 있으며, ARK 인베스트의 CEO인 캐시 우드는 <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared" target="_blank" rel="noopener">향후 5년간 바이오로직스</a> 분야에서 4,000억 달러의 시장 기회가 있을 것으로 예상하고 있다. 이 분야는 투자자들로부터 상당한 관심을 받고 있지만, 크리스퍼 테라퓨틱스(Crispr Therapeutics AG)와 인텔리아 테라퓨틱스(Intellia Therapeutics Inc.) 같은 회사는 상당한 시장 변동성을 보였다.
2021년 구글 딥마인드에서 분사한 아이소모픽 랩스는 기술 대기업들이 AI를 활용해 전통적으로 기간이 길고 비용이 많이 드는 신약 개발 과정을 간소화하려는 추세를 반영한다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A7%88%ED%8B%B4-%EC%8A%88%ED%81%AC%EB%A0%90%EB%A6%AC-%EC%B5%9C%EA%B7%BC-%EC%A3%BC%EA%B0%80-%EC%83%81%EC%8A%B9%EC%97%90%EB%8F%84-%EC%95%84%EC%9D%B4%EC%98%A8%ED%81%90%EB%A6%AC%EC%A0%9C/">마틴 슈크렐리, 최근 주가 상승에도 "아이온큐·리제티는 최고의 공매도 종목"</a>
이미지 제공: Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 작성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

GOOGL

NTLA

ORCL

알파벳 자회사 아이소모픽 랩스, 올해 말까지 AI가 설계한 신약 임상시험 예정

금요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)가 템퍼스 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 크리스퍼 테라퓨틱스 AG(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), 유아이패스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), 로블록스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>), 레딧(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>),애컬레이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) 그리고 아이보타(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>)와 관련된 중요한 거래를 진행했다.
템퍼스 AI 주식 거래
아크 인베스트의 Ark Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)와 Ark Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)가 템퍼스 AI 주식을 대량으로 구매했다. ARKG 펀드는 27,188주를 매수했고, ARKK 펀드는 무려 159,344주를 구매했다.
종가가 35.15달러인 것을 기준으로 이 거래의 총 가치는 약 657만 달러에 달합니다. 이는 아크 인베스트가 최근 인공지능(AI) 기반 회사에 투자하는 추세와 일치한다.
CRSP 주식 거래
아크 인베스트의 ARKG와 ARKK 펀드도 크리스퍼 테라퓨틱스 주식을 구매했다. ARKG 펀드는 21,730주를 매수했고, ARKK 펀드는 125,690주를 추가했다.
종가가 40.53달러인 것을 기준으로 이 거래의 총 가치는 약 596만 달러이다.
PATH, RBLX, RDDT 주식 거래
반면, 아크 인베스트는 유아이패스, 로블록스 그리고 레딧의 주식을 매도했습니다. ARKK 펀드는 유아이패스의 주식 199,224주, 로블록스의 주식 148,591주를 매도하고, ARKW 펀드는 레딧의 주식 5,215주를 매도했다.
이 매도는 아크 인베스트의 포트폴리오 전략의 변화를 나타낸다.
기타 주요 거래:
<ul>
<li>아이보타: 아크 인베스트의 Ark Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>) 펀드가 아이보타 주식 4,364주를 매수했다.</li>
<li>애컬레이드.: ARKG 펀드가 애컬레이드의 주식 284,775주를 매도했다.</li>
</ul>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BA%90%EC%8B%9C-%EC%9A%B0%EB%93%9C%EC%9D%98-%EC%95%84%ED%81%AC-%EC%9D%B8%EB%B2%A0%EC%8A%A4%ED%8A%B8-%ED%8C%94%EB%9E%80%ED%8B%B0%EC%96%B4-%EC%A3%BC%EA%B0%80-%ED%95%98%EB%9D%BD-%EC%86%8D-%EC%B6%94/" target="_blank" rel="noopener">캐시 우드의 아크 인베스트, 팔란티어 주식 다시 매도 &#8211; 2025년 첫 2주간 주가 15% 이상 하락</a></li>
</ul>
면책 조항: 이 콘텐츠는 AI 도구의 도움을 받아 부분적으로 생성되었으며, Benzinga 편집자가 검토하고 발행했습니다.
이미지 출처: Benzinga YouTube 및 Unsplash
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

IBTA

RDDT

아크 인베스트, 금요일 템퍼스 AI·크리스퍼 테라퓨틱스 매수 vs 유아이패스·로블록스·레딧 매도

아크 인베스트먼트 매니지먼트 설립자이자 CEO인 캐시 우드는 최근 소파이(SoFi)의 투자 전략 책임자 리즈 토마스(Liz Thomas)와 함께 출연한 팟캐스트에서 기술 혁신의 초석으로 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)를 강조하고, 인공지능(AI) 투자의 미래를 옹호했다.
무슨 일 있었나: ARK 이노베이션 ETF를 이끄는 것으로 널리 알려진 캐시 우드는 테슬라를 "지구상에서 가장 큰 AI 프로젝트"라고 표현하며 여러 분야에 걸쳐 AI의 혁신적 잠재력을 강조했다.
특히 AI와 시퀀싱 기술의 융합이 혈액 검사를 통한 암 진단, 특히 크리스퍼 유전자 편집 기능과 결합될 경우 암 진단에 혁신을 가져올 수 있는 의료 분야의 발전에 주목했다.
우드는 주요 기술 기업들의 막대한 GPU 및 클라우드 인프라 투자에 대한 우려를 언급하며 자본 지출 증가에 대한 투자자들의 회의적인 시각도 인정했다.
그는 아직 명확한 수익이 입증되지 않은 투자의 예로 18개월 만에 300억 달러에서 600억 달러로 지출이 급증한 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)를 들었다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%BA%90%EC%8B%9C-%EC%9A%B0%EB%93%9C-%EB%B0%94%EC%9D%B4%EC%98%A4-%EB%B6%84%EC%95%BC%EC%97%90%EC%84%9C-4%EC%B2%9C%EC%96%B5-%EB%8B%AC%EB%9F%AC-%EA%B8%B0%ED%9A%8C-%EC%A0%84%EB%A7%9D/">캐시 우드, 바이오 분야에서 4천억 달러 기회 전망</a>
왜 중요한가: 캐시 우드의 이번 발언은 주력 펀드를 통해 테슬라 보유 자산을 1,800만 달러 줄이는 등 최근 포트폴리오 조정 과정 속에 나왔다. 이러한 매각에도 불구하고 우드는 "1조 달러 이상의 수익 기회"를 예상하며 테슬라의 <a href="https://www.benzinga.com/24/11/42205945/ark-invests-bold-move-tesla-shares-sold-amid-market-shifts" target="_blank" rel="noopener">자율주행 잠재력</a>에 대해 낙관적인 장기 전망을 유지하고 있다.
우드의 투자 논리는 테슬라를 넘어 광범위한 생물학 분야로 확장되어 AI, 유전자 염기서열 분석, <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared" target="_blank" rel="noopener">유전자 편집 기술</a>의 융합으로 4,000억 달러의 시장 기회가 창출될 것으로 예상하고 있다.
11억 7,900만 달러의 자산을 운용하는 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)는 이러한 신념을 반영하여 트위스트 바이오사이언스 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), CRISPR 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) 같은 회사에 상당한 투자를 단행했다.
우드는 시장 밸류에이션 상승에 대한 우려에 대해 현재 20대 초반의 시장 멀티플은 오류의 여지가 거의 없다고 지적했다. 그러나 특히 AI와 의료 혁신의 교차점에서 <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared" target="_blank" rel="noopener">질병 치료 및 진단</a>의 혁신적인 발전 가능성을 보는 비즈니스 모델의 출현에 대해 여전히 확신을 가지고 있다.
이미지 출처: 아크 인베스트
면책 조항: 이 기사는 부분적으로 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>의 도움으로 작성되었으며 Benzinga 편집자가 검토 후 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

TSLA

TWST

캐시 우드 "테슬라는 지구상에서 가장 큰 AI 프로젝트", 기술 투자에 대해 우려하지 않아

아크 인베스트의 CEO인 캐시 우드는 인공지능, 유전자 염기서열(시퀀싱) 분석, 유전자 편집 기술의 교차점에서 전례 없는 잠재력을 발견하고 바이오 분야에 투자를 강화하고 있다.
무슨 일 있었나: 캐시 우드의 열정은 의료와 신약 개발에 혁명을 일으킬 수 있는 혁신적인 기술 융합에 집중되어 있다.
그는 이 분야에 대해 솔직하게 이야기하면서 특히 크리스퍼 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) 같은 회사에서 유전자 치료의 괄목할 만한 발전이 이루어지고 있다고 강조했다.
가장 눈에 띄는 사례는 최근 크리스퍼 테라퓨틱스가 겸상 적혈구 질환 치료 분야에서 거둔 획기적인 성과다. 우드는 이전에는 연간 12~20회 수혈을 받아야 했던 환자들이 이제 그런 수혈을 받지 않아도 될 수 있게 되었다고 언급했다.
이러한 전략은 치료의 혁신을 넘어 신약 개발 자체로 확장횐다. 우드는 리커전 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>)와 같은 회사가 인공지능을 활용하여 임상시험 실패율을 획기적으로 줄이고 신약 개발 일정을 앞당기고 있다고 강조했다.
그러나 이러한 혁신적인 기업들의 시장 성과는 좀 더 복잡한 이야기를 담고 있다. 올해 들어 이들 주식은 상당한 변동성을 보였다. <a href="//www.benzinga.com/pro/"" target="_blank" rel="noopener">벤징가 프로 데이터</a>에 따르면 연초 대비 크리스퍼 테라퓨틱스는 25.36% 하락, 인텔리아 테라퓨틱스는 52.21% 하락, 빔 테라퓨틱스는 3.04% 하락, 리커션 제약은 9.80% 하락했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space.
Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%BA%90%EC%8B%9C-%EC%9A%B0%EB%93%9C%EC%9D%98-%EC%95%84%ED%81%AC-%EC%9D%B8%EB%B2%A0%EC%8A%A4%ED%8A%B8-%ED%85%8C%EC%8A%AC%EB%9D%BC-%EC%A3%BC%EC%8B%9D-1800%EB%A7%8C-%EB%8B%AC%EB%9F%AC-%EC%83%81/" target="_blank" rel="noopener">캐시 우드의 아크 인베스트, 테슬라 주식 1,800만 달러 상당 매각</a>
왜 중요한가: 바이오 분야에 대한 아크 인베스트의 노력은 11억 7,900만 달러의 순자산을 관리하는 Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)를 통해 분명하게 드러난다. 이 펀드의 성과는 2020년 최고 180.50%에서 2022년 최저 -53.94%에 이르는 연간 수익률로 해당 섹터의 변동성을 반영하고 있다.
이 ETF의 현재 상위 보유 종목은 혁신적인 바이오 기술에 대한 캐시 우드의 전략적 초점을 강조한다. 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>)가 8.90%의 비중으로 포트폴리오를 이끌고 있으며, 크리스퍼 테라퓨틱스가 7.88%, 리커션 파마슈티컬스가 6.17%로 그 뒤를 잇고 있다. 그 밖의 주요 투자 기업으로는 케어DX(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) 등이 있으며, 이들은 게놈 및 생물학적 혁신에 대한 다양한 접근 방식을 대표한다.
캐시 우드는 AI, 시퀀싱 기술, 유전자 편집의 전례 없는 융합 덕분에 향후 5년 동안 바이오 분야에서 4,000억 달러의 시장 기회가 있을 것으로 전망한다.
이미지 출처: Ark Invest
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토 후 게시했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ADPT

CDNA

VCYT

캐시 우드, 바이오 분야에서 4천억 달러 기회 전망

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob" target="_blank" rel="noopener" data-google-interstitial="false">혁신 분야</a>에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다.
이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.
아크 이노베이션: 우드와 <a href="https://www.benzinga.com/topic/ark-funds">아크 펀드</a>는 Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 2014년 10월 31일에 출시했다. 이 펀드는 이 회사의 가장 유명하고 가장 큰 펀드로 성장했으며, 현재 57억 8천만 달러의 운용 자산을 보유하고 있다.
&#8220;ARRK는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 국내 및 해외 주식에 주로 투자하여 펀드의 투자 테마인 파괴적 혁신(disruptive innovation)와 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkk">웹사이트</a>에서 설명한다.
파괴적 혁신 테마에는 자율 이동성, 정밀 치료, 차세대 클라우드, 신경망, 지능형 기기, 디지털 지갑, 디지털 자산, 스마트 계약 및 멀티오믹 기술이 포함된다.
&#8220;ARK는 &#8216;파괴적 혁신&#8217;을 세상이 돌아가는 방식에 잠재적으로 도전할 수 있는 기술적으로 구현된 새로운 제품이나 서비스의 도입으로 정의한다.&#8221;
현재 ARKK ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 14.1%</li>
<li>로쿠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 10.8%</li>
<li>코인베이스 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 8.1%</li>
<li>로블록스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>): 6.2%</li>
<li>팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 5.1%</li>
<li>로빈후드 마켓 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 5.0%</li>
<li>블록 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>): 4.9%</li>
<li>크리스퍼 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): 4.5%</li>
<li>쇼피파이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 3.9%</li>
<li>유아이패스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): 2.9%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 161.4% 상승했다. 이 수익률은 S&amp;P 500을 추적하는 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)의 현재 10년 수익률에는 미치지 못한다.
아래의 표는 ARKK의 수익률이 SPY와 어떻게 비교되는지를 보여준다. SPY는 <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41407647/spy-reaches-600-billion-in-assets-oldest-us-ETF-hits-milestone-as-all-time-highs-conti">가장 오래되고 가장 큰</a> 미국 ETF이다:
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKK</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>+19.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-24.3%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>+2.6%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKK 설립 이래 2014년 10월 31일 기준</td>
<td>+10.2%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
아래의 차트는 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro</a>에서 제공한 ARKK의 10년 수익률을 보여준다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png" sizes="(max-width: 1003px) 100vw, 1003px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png 1003w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-768x393.png 768w" alt="" width="1003" height="513" /></a></figure>
비교를 위해 SPY의 10년 차트도 보여드리겠다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png" sizes="(max-width: 995px) 100vw, 995px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-768x392.png 768w" alt="" width="995" height="508" /></a></figure>
다음 읽어보기: <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">독점: 캐시 우드가 테슬라가 기술 주식으로 거래되어야 하는 이유를 Benzinga에 말했다.</a>
아크 지노믹스: Ark Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)는 2014년 10월 31일에 아크 펀드에 의해 출시되었다. 현재 이 ETF 펀드는 13억 3천만 달러의 자산을 운용하고 있다.
&#8220;ARKG는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 헬스 케어, 정보 기술, 소재, 에너지 및 소비재 등 여러 섹터의 국내외 주식에 주로 투자하며, 펀드의 투자 테마인 유전체 혁명(genomics revolution)과 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkg">웹사이트</a>에서 설명한다.
이 유전체 혁명 ETF의 테마에는 정밀 치료, 멀티오믹 기술, 프로그래머블 생물학, 신경망, 차세대 클라우드 및 적응형 로보틱스가 포함된다.
현재 ARKG ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>트위스트 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): 8.7%</li>
<li>리커젼 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>): 7.0%</li>
<li>크리스퍼 테라퓨틱스: 7.0%</li>
<li>케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>): 5.1%</li>
<li>어댑티브 바이오테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>): 4.7%</li>
<li>베라사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYCT#NASDAQ">VYCT</a>): 4.6%</li>
<li>아이오니스 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>): 4.3%</li>
<li>누릭스 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>): 4.1%</li>
<li>나테라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 3.8%</li>
<li>10x 지노믹스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): 3.8%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 38.9% 상승했다. 이 수익률은 현재 SPDR S&amp;P 500 ETF Trust의 10년 수익률에는 미치지 못한다.
ARKG의 수익률이 SPY와 어떻게 비교되는지를 살펴보겠다.
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKG</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>-7.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-29.9%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>-1.9%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKG 설립 이래 2014년 10월 31일 기준</td>
<td>+3.3%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
다음은 ARKG의 10년 차트다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624525" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png" sizes="(max-width: 993px) 100vw, 993px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-768x394.png 768w" alt="" width="993" height="510" /></a></figure>
중요성 (Why It&#8217;s Important): 위의 차트들은 ARKK와 ARKG가 모두 투자자들에게 몇 년 동안 강력한 성장과 수익률을 경험했지만, 최근 몇 년 동안은 더 넓은 S&amp;P 500 시장 지수를 하회한 것을 보여준다.
한때 이 ETF들은 가장 화제가 된 펀드들 중 하나였으며, 이 회사의 일일 거래 활동은 종종 주식을 상승시켰다. 이는 우드의 뛰어난 성과 덕분이다.
S&amp;P 500 ETF는 분기마다 리밸런싱을 하지만, 이 액티브하게 관리되는 펀드는 거의 매일 거래를 완료한다. 종종 주가가 상승하는 주식의 평균 매입가가 시간이 지남에 따라 상승하여 수익률에 부정적인 영향을 미칠 수 있다.
아크 펀드는 일반적으로 향후 5년에서 10년 동안 강력한 성장을 할 것으로 믿는 회사들에 투자한다. 이는 펀드의 수익률이 때때로 몇 년이 걸려야 나타날 수 있음을 의미한다.
우드는 엔비디아의 주식을 2014년에 약 5달러에 매수한 것과 같이 많은 테마에 대해 일찍 투자한 바 있다. 이는 가장 최근의 주식 분할 이전의 일이었다. 이 펀드는 나중에 2022년 말과 2023년 초에 이 포지션에서 완전히 매도하여 지난 2년 가까이 <a style="font-size: revert;" href="https://www.benzinga.com/general/education/24/02/37294405/heres-how-much-cathie-wood-ark-invest-flagship-fund-missed-by-selling-nvidia-early">엄청난 수익을 놓쳤</a>다.
이 펀드 매니저는 또한 테슬라 성장 스토리에 일찍 투자했다. 2018년 2월에 이 전기차 회사에 대해 $4,000 목표 주가를 <a href="https://www.benzinga.com/news/22/03/26046331/if-you-invested-1-000-in-tesla-when-cathie-wood-made-her-4-000-prediction-heres-how-much-youd-have-n-1" target="_blank" rel="noopener">예측</a>했다. 당시에는 가격 예측으로 비웃음거리가 되었지만, 주가는 2021년 1월에 분할 기준으로 목표 주가에 도달했다.
테슬라에 대한 예측이 맞아들어간 것은 우드의 펀드 매니저로서의 위상을 높이는 데 도움이 되었고, 아크 펀드 ETF들에 대한 관심이 증가하는 계기가 되었다.
최근 몇 년 동안 아크 펀드 ETF들에 대한 관심이 식었지만, 많은 투자자들은 여전히 그들의 영향을 기억하고 일일 거래 활동을 계속 추적하며, 우드가 향후 5년에서 10년 동안 보유할 주식을 주의 깊게 지켜보고 있다.

다음 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that">독점: 캐시 우드는 왜 비트코인이 100만 달러에 이를 것이라고 생각하는가? 그녀는 무엇을 알고 있기에?</a></li>
</ul>
이미지 제공: Ark Invest 및 Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Broad U.S. Equity ETFs

Education

HOOD

IONS

NRIX

NTRA

PLTR

ROKU

SHOP

VYCT

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&P 500과 비교

Comments

CRISPR Therapeutics

뉴스

에 대한 최신 뉴스 CRISPR Therapeutics (NASDAQ:CRSP) 주식

토요일, 4월 05, 2025

수요일, 3월 12, 2025

일요일, 2월 16, 2025

토요일, 2월 01, 2025

수요일, 1월 22, 2025

일요일, 1월 19, 2025

금요일, 11월 29, 2024

수요일, 11월 27, 2024

금요일, 11월 01, 2024

뉴스

파트너 / 기고자

벤징가 글로벌